Torrent Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.74×	0.71×	0.70×	0.67×
	0.73×	0.83×	0.91×	0.92×	0.87×
	22.2%	24.6%	25.4%	23.9%	22.2%
	0.47×	0.47×	0.77×	0.71×	0.68×
	2.43×	2.52×	1.97×	2.20×	2.42×
	13.8%	18.1%	25.2%	24.1%	21.3%
	27.1%	27.1%	26.5%	25.4%	20.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TORNTPHARM₹4,580.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA JBCHEPHARM MANKIND ZYDUSLIFE DIVISLAB MAXHEALTH DRREDDY CIPLAMcap ₹1.55L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.67	0.70	0.71	0.74	0.75
Interest Burden (Pretax/EBIT) ×	0.87	0.92	0.91	0.83	0.73
EBIT Margin %	22.19	23.86	25.41	24.61	22.17
Asset Turnover ×	0.68	0.71	0.77	0.47	0.47
Financial Leverage (Assets/Equity) ×	2.42	2.20	1.97	2.52	2.43
ROE (5-step product, year-end total equity) %	21.32	24.08	25.23	18.11	13.77
ROE (owners' profit / average owners' equity) %	20.49	25.37	26.46	27.07	27.07

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.